Active substanceCefoperazone + SulbactamCefoperazone + Sulbactam
Similar drugsTo uncover
  • Bakperazone
    powder w / m in / in 
  • Baktsefort
    powder w / m in / in 
    KRASFARMA, JSC     Russia
  • Sulzencef®
    powdersolution w / m in / in 
    SYNTHESIS, OJSC     Russia
  • Sulmover®
    powdersolution w / m in / in 
  • Sulmover®
    powdersolution w / m in / in 
  • Sulperazone
    powdersolution w / m in / in 
  • SULPERATEF®
    powdersolution w / m in / in 
    ABOLMED, LLC     Russia
  • Sulceph
    powdersolution w / m in / in 
    Medocemi Co., Ltd.     Cyprus
  • Cebanex
    powdersolution w / m in / in 
  • Cebanex
    powdersolution w / m in / in 
  • Cefbactam®
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • Cefoperazone and Sulbactam Jodas
    powdersolution w / m in / in 
    JODAS EKSPOIM, LLC     Russia
  • Cefoperazone and Sulbactam Spencer
    powdersolution w / m in / in 
    Spencer Pharma UK Limited     United Kingdom
  • Cefpar SV
    powdersolution w / m in / in 
  • Dosage form: & nbspPowder for the preparation of solution for intravenous and intramuscular injection.
    Composition:One bottle contains: sodium cefoperazone (in terms of cefoperazone) - 0.25 g; 0.5 g; 0.75 g; 1.5 g; 2.0 g and sodium sulbactam (in terms of sulbactam) 0.25 g; 0.5 g; 0.75 g; 1.5 g; 2.0 g.
    Description:White or almost white powder. Hygroscopic.
    Pharmacotherapeutic group:Antibiotic-cephalosporin + Dose changes may be required in case of severe bile duct obstruction, severe liver disease, as well as renal dysfunction associated with any of these conditions. In the treatment of cefoperazonom, as well as other antibiotics, in rare cases, vitamin K deficiency develops. Its cause is probably suppression of normal intestinal microflora, which synthesizes this vitamin. The risk group can include patients receiving malnutrition, patients with malabsorption (for example, in case of mu-koviscidosis) and for a long time on intravenous artificial feeding. In such cases, as well as in patients receiving indirect anticoagulants, it is necessary to monitor the international normalized ratio and, in the presence of indications, prescribe vitamin K. For long-term treatment with Sulmover®, as with other antibiotics,there may be an excessive growth of insensitive microorganisms. Patients should be carefully observed during treatment. With prolonged therapy, it is recommended to periodically monitor the performance of internal organs, including the kidneys, liver and hematopoiesis system. This is especially important for newborns, especially premature babies, and children under 1 year. Cefoperazone does not displace bilirubin from its association with plasma proteins. The efficacy and safety of the drug in infants and children under 1 year of age has not been adequately studied. Prior to the appointment of the drug, the potential benefit and the possible risk should be correlated. Lactamase inhibitor.
    ATX: & nbsp

    J.01.D.D.62   Cefoperazone in combination with other drugs

    Pharmacodynamics:
    Combined drug. Cefoperazone - cephalosporin antibiotic III generation, it acts bactericidal, has a wide spectrum of action; highly active against aerobic and anaerobic Gram-positive and Gram-negative microorganisms (including Pseudomonas aeruginosa), resistant to β-lactamases of Gram-positive and Gram-negative microorganisms.
    Sulbactam is an irreversible inhibitor of β-lactamases, which are released by microorganisms,resistant to β-lactam antibiotics; prevents the destruction of penicillins and cephalosporins under the action of β-lactamases of resistant microorganisms; binding to penicillin-binding proteins, shows a synergism with simultaneous application with penicillins and cephalosporins.
    The combination of sulbactam and cefoperazone is active against all microorganisms sensitive to cefoperazone and acts synergistically (up to 4 times the MIC of the combination as compared to the values ​​for each component alone) against microorganisms: Haemophilus influenzae, Bacteroides spp., Staphylococcus spp., Acinetobacter calcoaceticus, Enterobacter aerogenes, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Morganella morganii, Citrobacter freundii, Enterobacter cloacae, Citrobacter diversus.
    Cefoperazone in vitro is active against a wide range of microorganisms: gram-positive bacteria - Staphylococcus aureus (including strains that form and do not form penicillinases), Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes (beta-hemolytic strain of group A), Streptococcus agalactiae (beta-hemolytic strain of group B), most strains of beta-hemolytic Streptococcus spp., Enterococcus faecalis; Gram-negative bacteria - Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Haemophilus influenzae, Proteus mirabilis, Morganella morganii, Providencia rettgeri, Providencia spp., Serratia spp. (including Serratia marcescens), Salmonella spp., Shigella spp., Pseudomonas aeruginosa, Acinetobacter calcoaceticus, Neisseria gonorrhoeae, Neisseria meningitidis; Bordetella pertussis, Yersinia enterocolitica; anaerobic bacteria - Bacteroides fragilis, Fusobacterium spp., Peptococcus spp., Peptostreptococcus spp., Veillonella spp., Clostridium spp., Eubacterium spp., Lactobacillus spp.
    Pharmacokinetics:
    Both sulbactam and cefoperazone well distributed into various tissues and fluids, including bile, gall bladder, skin, appendix, fallopian tubes, ovaries, uterus, etc.
    The maximum concentrations of sulbactam and cefoperazone after intravenous administration of 1 g of sulbactam and 1 g of cefoperazone for 5 minutes averaged 130.2 and 236.8 μg / ml, respectively. This reflects a higher volume of distribution of sulbactam (Vd = 18.0-27.6 l) compared with that of cefoperazone (Vd = 10.2-11.3 l). There is no data on the presence of any pharmacokinetic interaction between sulbactam and cefoperazone when a combination of sulbactam and cefoperazone is administered. Approximately 84% of the dose of sulbactam and 25% of the dose of cefoperazone with the administration of a combination of sulbactam and cefoperazone are excreted by the kidneys. The rest of cefoperazone is excreted mainly with bile. When a combination of sulbactam and cefoperazone is administered, the half-life of the sulbactam averages about 1 hour, and cefoperazone is 1.7 hours. The serum concentration is proportional to the administered dose.
    When repeated use of significant changes in the pharmacokinetics of both components of the Sulmover® preparation was not noted. When the drug was administered every 8-12 h, cumulation was not observed.
    Indications:
    Treatment of infections caused by microorganisms sensitive to cefoperazone:

    - infections of the upper and lower respiratory tract, including sinusitis, pneumonia, pleural empyema, lung abscess;

    - bacterial meningitis;

    - uncomplicated and complicated infections of the abdominal organs, including cholecystitis, cholangitis, peritonitis, abscess of the abdominal cavity;

    - infectious and inflammatory diseases of the pelvic organs (endometritis, salpingoophoritis, pelvioperitonitis);

    - urinary tract infection (pyelitis, pyelonephritis);

    - skin and soft tissue infections caused by mixed aerobic-anaerobic flora;

    - septicemia;

    - infection of bones and joints;

    - gonorrhea.
    Contraindications:Sulmover® is contraindicated in patients with allergies to penicillins, sulbactam, cefoperazone or any other cephalosporins.
    When taking alcohol during treatment with cefoperazone and for up to 5 days after its administration, disulfiram-like reactions characterized by "hot flashes", sweating, headache and tachycardia were recorded. Similar reactions have been observed with some other cephalosporins, so patients should be warned about the possibility of their occurrence when consuming alcoholic beverages against the background of treatment with Sulmover®.Patients who need artificial feeding (inside or parenteral) should avoid using solutions containing ethanol.
    Carefully:Assign the drug for severe violations of liver and kidney function, colitis (including in the anamnesis), in preterm infants and children under 1 year.
    Pregnancy and lactation:
    Sulbactam and cefoperazone penetrate the placenta. Adequate and strictly controlled studies of drug safety during pregnancy have not been conducted. The results of research on the effect of drugs on reproductive function in animals do not always allow predicting effects in humans, so the drug should be used during pregnancy only when the expected benefit for the mother exceeds the potential risk to the fetus.
    Sulbactam and cefoperazone are excreted in breast milk in very small quantities. Although both components do not penetrate breast milk, nevertheless, treatment with the drug during breastfeeding should only be carried out if the potential benefit exceeds the potential risk.
    Dosing and Administration:

    Application in adults

    In adults, Sulmover® is recommended to be used in a daily dose of 2-4 g. In severe or refractory infections, the daily dose of the drug can be increased to 8 g. Since the recommended maximum daily dose of sulbactam is 4 g, patients receiving Sulmover® in severe infections may require additional administration of cefoperazone.

    The dose should be divided into equal parts and administered every 12 hours.

    Application for violations of the liver and kidneys

    In patients with creatinine clearance of 15-30 ml / min, the maximum dose of sulbactam is 1 g every 12 hours (maximum daily dose of sulbactam 2 g), and in patients with creatinine clearance less than 15 ml / min the maximum dose of sulbactam is 500 mg every 12 hours the maximum daily dose of sulbactam 1 g). In severe infections, additional administration of cefoperazone may be required.

    With hemodialysis, the pharmacokinetics of sulbactam significantly change and the half-life of cefoperazone from the serum decreases slightly. Therefore, the administration of Sulmover® should be performed after dialysis.

    In patients with impaired liver function and concomitant renal dysfunction, monitoring the serum concentration of cefoperazone and correcting its dose should be necessary.If regular monitoring of serum concentration of cefoperazone in such cases is not carried out, then its daily dose should not exceed 2 g.

    Application the children

    In children, Sulmover® is recommended to be used in a daily dose of 40-80 mg / kg per day. The maximum daily dose of sulbactam in children should not exceed 80 mg / kg per day. In severe or refractory infections, the dose of the drug can be increased to 160 mg / kg per day.

    The dose should be divided into equal parts and administered every 6-12 hours. In newborns during the first week of life, the drug should be injected every 12 hours.

    Method of preparing a solution for parenteral use

    Sulmover® is compatible with water for injection, 5% dextrose solution, 0.9% sodium chloride solution, 5% dextrose solution in 0.225% sodium chloride solution and 5% dextrose solution in 0.9% sodium chloride solution in concentrations from 10 mg / ml of cefoperazone and 5 mg / ml of sulbactam to 250 mg / ml, respectively.

    Total dose (g)

    Equivalent doses of sulbactam + cefoperazone (d)

    Minimum volume of solvent, ml

    Maximum final concentration (mg / ml)

    0,5

    0,25 + 0,25

    2

    125 + 125

    1,0

    0,5 + 0,5

    4

    125 + 125

    1,5

    0,75 + 0,75

    6

    125 + 125

    3,0

    1,5 + 1,5

    12

    125 + 125

    4,0

    2,0 + 2,0

    16

    125 + 125

    Intravenous administration.

    For intravenous bolus administration (intravenous injection), the contents of the vial are dissolved in 20 ml of the solvent and injected for a minimum of 3 minutes.For intravenous infusion administration, the preparation is dissolved, as indicated above, diluted to 50-100 ml, using for dilution any of these solvents except for water for injection, and injected for 30-60 minutes.

    To prepare a solution for intravenous infusion, Ringer's lactate solution can be used, but it can not be used to initially dissolve the powder, given the incompatibility of this mixture. Compatibility can be achieved by a two-stage solution preparation: first use sterile water for injection (see table above) and then dilute the resulting solution with Ringer's lactate solution to a concentration of 5 mg / ml of sulbactam (2 ml of the initial solution is diluted in 50 ml Ringer's solution lactate or 4 ml in 100 ml Ringer's solution of lactate).

    Intramuscular injection

    To prepare the solution for intramuscular injection, use sterile water for injection. You can also use a 2% solution of lidocaine, but it can not be used to initially dissolve the powder, given their incompatibility. The solution containing cefoperazone in a concentration of 250 mg / ml or more, is prepared in two steps: first, use sterile water for injection (see Table.above), then diluted with 2% lidocaine solution to obtain a 0.5% lidocaine solution.

    Side effects:

    When using Sulmover®, the following side effects may occur.

    Allergic reactions: anaphylactic shock.

    From the cardiovascular system: lowering of arterial pressure, vasculitis.

    On the part of the hematopoiesis system: decrease in the number of neutrophils. With long-term treatment (as with other β-lactam antibiotics), reversible neutropenia may develop. In some patients, a positive Coombs test was observed during treatment. There is also a decrease in hemoglobin and hematocrit. Transient eosinophilia, leukopenia and thrombocytopenia, as well as hypoprothrombinemia, were observed. Possible bleeding associated with vitamin K deficiency.

    From the gastrointestinal tract: diarrhea, nausea, vomiting, pseudomembranous colitis.

    Skin reactions: maculopapular rash, hives, itching, Stevens-Johnson syndrome. Their risk is higher in patients with allergic reactions in the anamnesis.

    Others: headache, fever, chills.

    Laboratory indicators: transient increase in liver function indices - alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and serum bilirubin concentration, hematuria, hypercreatininaemia.

    Local reactions: Sulmover® is well tolerated by intramuscular injection. Sometimes, after intramuscular injection, transient pain is observed. When intravenously injected with a catheter (as well as other cephalosporins and penicillins), phlebitis may develop at the site of infusion.

    Overdose:
    Symptoms: it is possible to expect the appearance of undesirable effects registered with the use of the drug (nausea, vomiting, fever); a high concentration of β-lactam antibiotics in the cerebrospinal fluid can lead to neurologic disorders, including convulsions.
    Treatment: symptomatic and supportive therapy. In severe cases - hemodialysis, especially in case of an overdose in patients with impaired renal function.
    Interaction:
    Solutions of sulbactam / cefoperazone and aminoglycosides should not be directly mixed, given the pharmaceutical incompatibility between them.If combined therapy with Sulmover® and aminoglycoside is carried out, the two drugs are administered by successive infusions using separate secondary catheters, and the primary catheter between the administration of the doses of preparations is washed with the solvent used. The intervals between the administration of Sulmover® and aminoglycoside during the day should be as large as possible.
    The simultaneous use of Sulmover® and the following drugs is not allowed: meclofenoxate, doxycycline, hydroxyzine, procainamide, aminophylline, aprotinin, pentazocine, cytochrome C.
    With the simultaneous use of Sulmover® and indirect anticoagulants, fibrinolytic drugs, sulphinpyrazone, non-steroidal anti-inflammatory drugs, especially acetylsalicylic acid and other salicylic acid derivatives, bleeding is possible.
    The drug Sulmover® is pharmaceutically incompatible with preparations of blood and its components and protein hydrolysates.
    When using a Benedict or Felling test, a false-positive reaction to glucose in the urine can be observed.
    Special instructions:
    Given the wide spectrum of action of Sulmover®, in most infections, monotherapy with this drug is effective. However, if necessary, Sulmover® can be used in combination with other antibiotics. With simultaneous use of aminoglycoside, kidney function should be monitored.
    Patients who received β-lactams, including cephalosporins, described cases of severe hypersensitivity reactions (anaphylactic), which sometimes led to death. The risk of such reactions is higher in patients who have a history of hypersensitivity reactions. In case of an allergic reaction, it is necessary to cancel the drug and prescribe adequate therapy.
    Serious anaphylactic reactions require urgent epinephrine. According to the indications, oxygen, intravenously injected glucocorticosteroids and provide airway patency, including intubation.
    Dose changes may be required in cases of severe bile duct obstruction, severe liver disease, and renal dysfunction associated with any of these conditions.
    In the treatment of cefoperazonom, as well as other antibiotics, in rare cases, vitamin K deficiency develops.The reason for it is probably suppression of normal intestinal microflora, which synthesizes this vitamin. The risk group can include patients receiving malnutrition, patients with malabsorption (for example, in case of mu-koviscidosis) and for a long time on intravenous artificial feeding. In such cases, as well as in patients receiving indirect anticoagulants, it is necessary to monitor the international normalized attitude and, in the presence of indications, prescribe vitamin K.
    With prolonged treatment with Sulmover®, as with other antibiotics, excessive growth of insensitive microorganisms can be observed. Patients should be carefully observed during treatment. With prolonged therapy, it is recommended to periodically monitor the performance of internal organs, including the kidneys, liver and hematopoiesis system. This is especially important for newborns, especially premature babies, and children under 1 year. Cefoperazone Do not displace bilirubin from the connection with plasma proteins.
    The efficacy and safety of the drug in infants and children under 1 year of age has not been adequately studied. Prior to the appointment of the drug should be related to the potential benefits and possible risks.
    Effect on the ability to drive transp. cf. and fur:The effect of the drug on the ability to drive vehicles and mechanisms is not established. However, patients experiencing fatigue, drowsiness, or disorientation during the period of drug use should refrain from engaging in potentially dangerous activities requiring increased concentration and speed of psychomotor reactions.
    Form release / dosage:
    Powder for the preparation of solution for intravenous and intramuscular injection.
    Packaging:
    0.25 g + 0.25 g; 0.5 g + 0.5 g; 0.75 g + 0.75 g; 1.5 g + 1.5 g; 2.0 g + 2.0 g of active substances in a vial of colorless glass of type 1 with a halobutyl rubber stopper and a cap of combined aluminum-plastic.
    One bottle together with instructions for use in a cardboard tutu. For 10 packs in a cardboard box.
    Storage conditions:In a dry, the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:
    2 years. Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-000972
    Date of registration:18.10.2011
    Date of cancellation:2016-10-18
    The owner of the registration certificate:Suzhou Dunrais Pharmaceutical Co., Ltd. Ltd.Suzhou Dunrais Pharmaceutical Co., Ltd. Ltd. China
    Manufacturer: & nbsp
    Representation: & nbspInstitute of Health CJSCInstitute of Health CJSC
    Information update date: & nbsp26.10.2015
    Illustrated instructions
      Instructions
      Up